Clinical Efficacy of Bendamustine Plus Rituximab (BR) for B-cell Relevant Indolent Non-Hodgkin’s Lymphoma and Role of <i>β</i>2-MG in Predicting the Efficacy of BR Regimen: A Real-World Retrospective Study in China

<div>Survival curves: (a) PFS; (b) OS.</div>

Computational and Mathematical Methods in Medicine

fig1

Figure 1

Figure 1: Clinical Efficacy of Bendamustine Plus Rituximab (BR) for B-cell Relevant Indolent Non-Hodgkin’s Lymphoma and Role of <i>β</i>2-MG in Predicting the Efficacy of BR Regimen: A Real-World Retrospective Study in China 

Figure 1 | Clinical Efficacy of Bendamustine Plus Rituximab (BR) for B-cell Relevant Indolent Non-Hodgkin’s Lymphoma and Role of β2-MG in Predicting the Efficacy of BR Regimen: A Real-World Retrospective Study in China 